**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event\* Drug interaction

A 52-year-old woman exhibited increased tacrolimus blood trough levels following concomitant administration of tacrolimus as a immunosuppressive therapy and off-label lopinavir/ritonavir for coronavirus disease 2019 (COVID-19) pneumonia . Additionally, she received off-label treatment with hydroxychloroquine and colchicine for COVID-19 pneumonia \[*routes and duration of treatments to reaction onset not stated; not all dosages stated*\].

The woman, who had undergone kidney transplantation, was hospitalised due to 1-day history of fever, dyspnoea, diarrhoea and myalgia at 8 months post-transplantation in March 2020. Her medical history was significant for hypertension, and she had received an unspecified flu vaccination. She had received induction immunosuppressive therapy with antithymocyte globulin \[Thymo\], followed by maintenance therapy with tacrolimus, unspecified steroids and mycophenolate mofetil. At admission, several investigations led to the diagnosis of COVID-19 pneumonia. At the time of infection diagnosis, she developed acute kidney injury. Her tacrolimus and mycophenolate mofetil treatments were stopped, and she received off-label treatment with hydroxychloroquine 200mg twice daily and lopinavir/ritonavir. Despite stopping tacrolimus therapy, her tacrolimus blood trough levels elevated at 39.9 µg/L secondary to tacrolimus and lopinavir/ritonavir interaction and due to underlying transient liver failure. On day 6 of the admission, she showed signs of systemic inflammation. Due to the progressive worsening of respiratory conditions, she received off-label colchicine 1mg on day 8, followed by 0.5 mg/day to reduce inflammation. Her anti-retroviral therapy with lopinavir/ritonavir was stopped after 24h of colchicine initiation. Subsequently, her respiratory conditions and systemic inflammation improved. She remained stable thereafter on non-invasive ventilation positive airway pressure. Her tacrolimus trough levels also returned to the target range.

The woman was re-initiated on tacrolimus on day 12 of the admission.
